1 Madeira, M., Mattar, A., Logullo, A. F., Soares, F. A. & Gebrim, L. H. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer 13, 425, doi:10.1186/1471-2407-13-425 (2013).
2 Pons, D. G. et al. The presence of Estrogen Receptor beta modulates the response of breast cancer cells to therapeutic agents. Int J Biochem Cell Biol 66, 85-94, doi:10.1016/j.biocel.2015.07.014 (2015).
3 Yager, J. D. & Davidson, N. E. Estrogen carcinogenesis in breast cancer. N Engl J Med 354, 270-282, doi:10.1056/NEJMra050776 (2006).
4 Keen, J. C. & Davidson, N. E. The biology of breast carcinoma. Cancer 97, 825-833, doi:10.1002/cncr.11126 (2003).
5 Nilsson, S., Koehler, K. F. & Gustafsson, J. A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 10, 778-792, doi:10.1038/nrd3551 (2011).
6 Chen, J. Q., Delannoy, M., Cooke, C. & Yager, J. D. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 286, E1011-1022, doi:10.1152/ajpendo.00508.2003 (2004).
7 Yang, S. H. et al. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A 101, 4130-4135, doi:10.1073/pnas.0306948101 (2004).
8 Nathan, M. R. & Schmid, P. The emerging world of breast cancer immunotherapy. Breast, doi:10.1016/j.breast.2017.05.013 (2017).
9 Amaral, C. et al. Steroidal aromatase inhibitors inhibit growth of hormone-dependent breast cancer cells by inducing cell cycle arrest and apoptosis. Apoptosis 18, 1426-1436, doi:10.1007/s10495-013-0879-6 (2013).
10 Gul, O., Basaga, H. & Kutuk, O. Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic 7, 27-34, doi:10.1093/bfgp/eln002 (2008).
11 Brunelle, J. K. & Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122, 437-441, doi:10.1242/jcs.031682 (2009).
12 Ryan, J. A., Brunelle, J. K. & Letai, A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci U S A 107, 12895-12900, doi:10.1073/pnas.0914878107 (2010).
13 Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365, doi:10.1016/j.ccr.2006.03.027 (2006).
14 Del Gaizo Moore, V. et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117, 112-121, doi:10.1172/JCI28281 (2007).
15 Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334, 1129-1133, doi:10.1126/science.1206727 (2011).
16 Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977-989, doi:10.1016/j.cell.2015.01.042 (2015).
17 Villalobos-Ortiz, M., Ryan, J., Mashaka, T. N., Opferman, J. T. & Letai, A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ 27, 999-1007, doi:10.1038/s41418-019-0391-9 (2020).
18 Brown, I. et al. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 6, R601-607, doi:10.1186/bcr918 (2004).
19 Sareddy, G. R. et al. Selective Estrogen Receptor beta Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6, 24185, doi:10.1038/srep24185 (2016).
20 Zhao, L. et al. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. Proc Natl Acad Sci U S A 115, E3673-E3681, doi:10.1073/pnas.1803291115 (2018).
21 Wolff, M., Kosyna, F. K., Dunst, J., Jelkmann, W. & Depping, R. Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells. Arch Biochem Biophys 613, 23-30, doi:10.1016/j.abb.2016.11.002 (2017).
22 Ma, R. et al. Estrogen Receptor beta as a Therapeutic Target in Breast Cancer Stem Cells. J Natl Cancer Inst 109, 1-14, doi:10.1093/jnci/djw236 (2017).
23 Honma, N. et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26, 3727-3734, doi:10.1200/JCO.2007.14.2968 (2008).
24 Bhola, P. D. et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal 13, doi:10.1126/scisignal.aay1451 (2020).
25 Brunelle, J. K., Ryan, J., Yecies, D., Opferman, J. T. & Letai, A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol 187, 429-442, doi:10.1083/jcb.200904049 (2009).
26 Pedram, A., Razandi, M., Wallace, D. C. & Levin, E. R. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17, 2125-2137, doi:10.1091/mbc.e05-11-1013 (2006).
27 Razandi, M., Pedram, A., Jordan, V. C., Fuqua, S. & Levin, E. R. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 32, 3274-3285, doi:10.1038/onc.2012.335 (2013).
28 Yager, J. D. & Chen, J. Q. Mitochondrial estrogen receptors--new insights into specific functions. Trends Endocrinol Metab 18, 89-91, doi:10.1016/j.tem.2007.02.006 (2007).
29 Maran, A., Zhang, M., Kennedy, A. M. & Turner, R. T. ER-independent actions of estrogen and estrogen metabolites in bone cells. J Musculoskelet Neuronal Interact 3, 367-369; discussion 381 (2003).
30 Yue, W. et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer 127, 1748-1757, doi:10.1002/ijc.25207 (2010).
31 Fitts, J. M., Klein, R. M. & Powers, C. A. Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor alpha/estrogen receptor beta, G protein-coupled estrogen receptor, or estrogen-related receptor gamma using fulvestrant (ICI 182780). J Pharmacol Exp Ther 338, 246-254, doi:10.1124/jpet.110.173955 (2011).
32 Ingle, J. N. et al. Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor alpha. Clin Cancer Res 26, 2986-2996, doi:10.1158/1078-0432.CCR-19-3091 (2020).
33 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408, doi:10.1006/meth.2001.1262 (2001).
34 Ryan, J. & Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61, 156-164, doi:10.1016/j.ymeth.2013.04.006 (2013).
35 Dasgupta, S., Hoque, M. O., Upadhyay, S. & Sidransky, D. Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res 68, 700-706, doi:10.1158/0008-5472.CAN-07-5532 (2008).
36 Manders, E. M. M., Verbeek, F.J., Aten, J.A. Measurement of co-localization of objects in dualcolor
confocal images. Journal of Microscopy 169, 375-382 (1993).
37 Hall, J. M. & McDonnell, D. P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578, doi:10.1210/endo.140.12.7179 (1999).
38 Eriksson, M. et al. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. Mol Cell Biol 37, doi:10.1128/MCB.00328-17 (2017).
39 Kale, J. et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep 19, doi:10.15252/embr.201745235 (2018).
40 Kutuk, O. et al. Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells. PLoS One 12, e0182809, doi:10.1371/journal.pone.0182809 (2017).